Coronary Artery Disease
Conditions
Interventions
IVUS guided:IVUS
OCT guided:OCT
Sponsors
Beijing Anzhen Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The age is over 18 years old, and the gender is not limited; 2. LM terminal in situ bifurcation lesions (visual inspection of Medina 1,1,1 or 0,1,1); 3. The anatomical structure is suitable for PCI; 4. Sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. STEMI occurred within 1 month before screening; 2. Patients who have previously undergone LM percutaneous coronary stenting (PCI) or coronary artery bypass grafting (CABG); 3. Patients with lesions involving the opening of the LM; 4. Patients with chronic total occlusion (CTO) lesions requiring intervention; 5. Patients with cardiogenic shock, pulmonary edema or LVEF 5 times the upper limit of normal) or renal insufficiency (eGRF<30mL/min/1.73m^2); 7. Patients who are to be implanted with bare stent (BMS)\bioresorbable stent (BVS); 8. Patients with second and third degree atrioventricular block (AVB) or malignant ventricular arrhythmia; 9. Patients with severe valve disease; 10. Ischemic cerebrovascular events occurred within half a year, or patients with residual neurological disorders; 11. Patients who cannot tolerate dual antiplatelet therapy after surgery; 12. Severe diseases with a life expectancy of less than 12 months, such as cancer, other advanced diseases, etc.; 13. Patients with active infection; 14. Hgb < 90g/L; 15. Active bleeding and obvious bleeding tendency, such as active ulcer, history of hemorrhagic stroke, intracranial space-occupying lesions, recent craniocerebral trauma, active bleeding of other organs that are not easy to stop bleeding, etc.; 16. Pregnant and lactating women; 17. Females of childbearing age with positive blood pregnancy or urine pregnancy test results within 24 hours before study treatment; 18. Males and females with reproductive potential do not use effective contraceptive measures or do not agree to continue to take effective contraceptive measures for at least 6 months after the last study drug administration; 19. Investigators believe that those who are not suitable for inclusion in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 12-month postoperative target lesion failure rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cardiogenic death 12 months postoperatively;Target lesion-related myocardial infarction 12 months postoperatively;Ischemia-driven target lesion revascularization 12 months postoperatively; | — |
Countries
China
Contacts
Public ContactYong Zeng
Beijing Anzhen Hospital, Capital Medical University
Outcome results
None listed